CCL18 and breast carcinoma: To identify the relationship between IL-32θ and breast cancer under the effect of TAMs, we divided the breast tumor tissues in two groups according to CD206 expression (an M2 macrophage marker), with a CD206+ status (n = 33) and CD206− tissues (n = 57) and measured CCL18, IL-1β, TNF-α, and CCL5 mRNA by RT-qPCR (Fig. 1a).